Focus on Nutrition and Gastrointestinal Tumors
Introducing the new interdisciplinary Karger journal

*Biomedicine Hub* is an interdisciplinary journal: a ‘hub’ for researchers, clinicians and public health professionals across biomedical disciplines to share research findings, ideas, theories, experimental results and clinical experience. *Biomedicine Hub* aims at facilitating the exchange of knowledge between disciplines, with a focus on translational science for the development of cutting-edge technologies and the improvement of health care. A further focus is on emerging interdisciplinary fields at the forefront of medicine.

Karger premium quality – open access – peer-reviewed – rapid publication

Get the full picture on [www.biomedicinehub.com](http://www.biomedicinehub.com)

- 16 internationally renowned senior editors
- over 170 Editorial Board Members
- from 35 countries
- specialized in 41 medical disciplines

*We invite you to submit now!* Article Processing Charges (APC) are waived before June 30, 2016. [www.karger.com/bmh_guidelines](http://www.karger.com/bmh_guidelines) Visit us on Facebook
Gastro Intestinal Tumors

Founded 2013 by J.-Y. Fang and P. Malfertheiner

Editors

Jing-Yuan Fang – Renji Hospital, Shanghai, China
Peter Malfertheiner – University Hospital Magdeburg, Magdeburg, Germany

Editorial Board

Christoph Auernhammer – University of Munich, Munich, Germany
Markus W. Büchler – University of Heidelberg, Heidelberg, Germany
Ying-Xuan Chen – Shanghai Jiaotong University, Shanghai, China
Yasuhiro Kodera – Nagoya University, Nagoya, Japan
Klaus Mönkemüller – Basil I. Hirschowitz Endoscopic Center of Excellence, Birmingham, USA
Goro Nakayama – Nagoya University, Nagoya, Japan
Yong-Zhan Nie – Xijing Hospital, Xi’an, China
Gerhard Rogler – University Hospital Zurich, Zurich, Switzerland
Masao Tanaka – Kyushu University, Fukuoka, Japan
Shuiping Tu – Shanghai Jiaotong University, Shanghai, China
J. John B. van Lanschot – Erasmus Medical Center, Rotterdam, The Netherlands
Bertram Wiedenmann – Charité-University Medicine Berlin, Berlin, Germany
Kai-Chun Wu – Xijing Hospital, Xi’an, China
Wei-Fen Xie – Changzheng Hospital, Shanghai, China
Hui-Ping Xue – Renji Hospital, Shanghai, China

KARGER 125

Printed in Germany on acid-free and non-aging paper (ISO 9706) by Stückle Druck, Ettenheim
Guidelines for Authors

**Aims and Scope**

Gastrointestinal Tumors is an international, peer-reviewed journal that brings together the leading opinions in all fields related to gastrointestinal cancer research. Ranging from the identification of new therapeutic targets to epidemiology, disease prevention, treatment and patient management, the journal provides a platform for the dissemination of key opinions from thought leaders in the field. By publishing timely reviews and original papers covering the latest developments, the journal will help readers gain insight into the evolving body of research across the relevant disciplines.

**Submission**

The Journal accepts Review Articles and Original Papers. Manuscripts should be submitted using the online submission website: www.karger.com/gat

Should you experience any problems with your submission, please contact:

gat@karger.com

Editorial Office ‘Gastrointestinal Tumors’

Karger AG

PO Box

CH–4009 Basel (Switzerland)

Tel. +41 61 306 1343

Fax +41 61 306 1234

All manuscripts must be accompanied by a cover letter and submission statement signed by all authors. Authors need not be from the same institution as the authors. The Editors make a final decision on all papers submitted to the journal and are responsible to maintain high quality peer-review.

**Conflicts of Interest**

Authors are required to disclose any financial (funding, stocks, patents, employment, honoraria, royalties) or non-financial (political, personal, professional) interests/relationships that may be interpreted to have influenced the manuscript. Conflicts of Interest Statements will be published at the end of the manuscript. If there is no conflict of interest, please state “The authors declare no conflicts of interest”.

**Ethics**

Research must comply with the guidelines for human studies and animal welfare regulations. Manuscripts reporting studies on human subjects should include evidence that the research was ethically conducted in accordance with the World Medical Association Declaration of Helsinki. In particular, authors must state in ‘Statement of Ethics’ at the end of the manuscript that subjects (or their parents or guardians) have given their informed written consent and that the study protocol was approved by an appropriate ethics committee. All patients should be identified by numbers or aliases, not by their real names. For clinical trials, registration in a public trials registry at or before the time of first patient enrollment is a condition of consideration for publication. The trial registration number must be provided upon submission. Authors should also state that animal experimentation was approved by the appropriate institutional review body. Copies of these guidelines and policy statements must be available for review by the editors if necessary.

**Plagiarism Policy**

Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation.

If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

**Arrangement**

The manuscript should conform to the following order: title page, abstract and key words, body, acknowledgments, references, figure legends, tables and figures. Manuscripts should be written in high-quality English suitable for effective communication to a professional medical audience. For authors whose native language is not English, use of a professional language editing service (http://www.karger.com/Resources/Authors) prior to submission can help to avoid delays with the review process.

All pages, including the figure legends, should be numbered in sequence, and the first author’s name should appear at the upper right corner of each page. Pages not conforming to the journal style will be returned without review.

**Title page:** The first page of each paper should indicate a concise title of no more than 150 characters, all authors’ names (first name and surname), authors’ institutional affiliations, and a short title for use as running head.

**Corresponding author:** The exact postal address of author(s) to whom correspondence, proofs, and reprint requests should be sent, including the postal code, must be given at the bottom of the title page. Please also supply phone number and e-mail address.

**Abstract of Review Articles:** Should be divided into the following subsections: Background, Summary, Key Message and Practical Implications. The Background should provide a brief history of the question and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Message encapsulates the main conclusions of the review. Submit a single abstract on a separate page. The abstract should be less than 300 words.

**Abstracts of Original Papers:** Each paper needs an abstract of up to 300 words. It should be structured as follows:

**Background/Aim:** What is the major problem that prompted the study?

**Methods:** How was the study performed?

**Results:** Most important findings?

**Conclusion:** Implications, future directions

**Key words:** Following the abstract, an alphabetical list of five key words that reflect the content of the paper should be given.

**Footnotes:** Avoid footnotes.

---

**Tables and illustrations:** Tables and illustrations (both numbered in sequential Arabic numerals) should be prepared as separate files. Tables require a brief and concise heading. Figures require a legend, prepared as a separate page, after references. Please use scale markers for electron micrographs, and indicate the type of stain used. For the reproduction of illustrations, only good drawings and original photographs can be accepted; negatives or photocopies cannot be used. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 x 223 mm) or provide crop marks. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi.

**References:** In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably please cite all authors.
Guidelines for Authors

Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples


(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum leukotriene-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 2005/06:3835.


Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)

S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Author’s Choice™

Karger’s Author’s Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must:

- Follow the terms of the relevant Creative Commons license
- Be linked to the final version on www.karger.com
- Include the following statement: ‘The final, published version of this article is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Funding Organizations (NIH etc.)

The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author’s Choice™, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC. Authors should include information on their grants in the Acknowledgments section of their papers.

Proofs

Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

Reprints

Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
Contents

See the journal website for contents
8th European Multidisciplinary Colorectal Cancer Congress
11 - 13 December 2016
Amsterdam, the Netherlands
WWW.EMCCC2016.ORG

Abstract Deadline: 1 September 2016
The International Liver Cancer Association Announces its 10th Annual Conference

ILCA 2016
9–11 September 2016
Vancouver, Canada

Conference Highlights:
State-of-the-Art Lectures
Cutting Edge Symposia
General Sessions
Interactive Luncheon Workshops
e-Poster Viewing Tours
Industry Exhibition
Networking Breaks and Reception

The international multidisciplinary forum for liver cancer experts around the latest innovations in research and care

Abstract submissions deadline: 16 April 2016
Early registration deadline: 8 July 2016

ilca2016.org
Digestive Surgery presents a comprehensive overview in the field of gastrointestinal surgery. Interdisciplinary in scope, the journal keeps the specialist aware of advances in all fields that contribute to improvements in the diagnosis and treatment of gastrointestinal disease. Particular emphasis is given to articles that evaluate not only recent clinical developments, especially clinical trials and technical innovations such as new endoscopic and laparoscopic procedures, but also relevant translational research. Each contribution is carefully aligned with the need of the digestive surgeon. Thus, the journal is an important component of the continuing medical education of surgeons who want their practice to benefit from a familiarity with new knowledge in all its dimensions.

Selected contributions
- Beyond Lactate: Is There a Role for Serum Lactate Measurement in Diagnosing Acute Mesenteric Ischemia? Demir, I.E.; Ceyhan, G.O.; Friess, H. (Munich)
- Comparative Analysis of Five-Year Survival Results of Laparoscopy-Assisted Gastrectomy versus Open Gastrectomy for Advanced Gastric Cancer. A Case-Control Study Using a Propensity Score Method: Kim, K.-H.; Kim, M.-C.; Jung, G.-J.; Choi, H.-J.; Jang, J.-S.; Kwon, H.-C. (Busan)
- Overview of Adjuvant and Neoadjuvant Therapy for Resectable Gastric Cancer in the East: Fujitani, K. (Osaka)
- Gastric Cancer Pathology and Underlying Molecular Mechanisms: Grabisch, H.I. (Leeds); Tan, P. (Singapore)
- Gastric Bypass: Current Results and Different Techniques: Vines, L.; Schiesser, M. (St. Gallen)
- Physiological Mechanisms behind Roux-en-Y Gastric Bypass Surgery: Lutz, T.A.; Bueter, M. (Zurich)
Indocyanine green (ICG) fluorescence has been used for imaging purposes for more than half a century; first employed by ophthalmologists for visualizing the retinal artery in the late 1960s, the application of ICG fluorescence imaging has since been continuously expanded. Recently, advances in imaging technologies have led to renewed attention regarding the use of ICG in the field of hepatobiliary surgery, as a new tool for visualizing the biliary tree and liver tumors.

This book introduces cutting-edge knowledge about fluorescence imaging techniques using both ICG and other new promising chemicals. After an introductory chapter on the history and basic technique of fluorescence imaging for hepatobiliary-pancreatic surgery, various clinical applications of ICG fluorescence imaging are discussed. These range from the identification of various malignancies to the use of imaging in surgery. The last part of this publication is dedicated to an outlook on near-future technology.
Advances in Management of Hepatocellular Cancer

Editors
Yoshikuni Kawaguchi
Norihiro Kokudo

Contents

Foreword: Kokudo, N.; Kawaguchi, Y.

Hepatology
- Biology of Hepatocellular Carcinoma: Critelli, R.M.; De Maria, N.; Villa, E.
- Serum Amyloid A-Positive Hepatocellular Neoplasm: A New Type of Tumor Arising in Patients with Advanced Alcoholic Disease: Sasaki, M.; Nakanuma, Y.
- Predictors of Microvascular Invasion in Hepatocellular Carcinoma: Yamashita, Y.; Shirabe, K.; Aishima, S.; Maehara, Y.

Non-Surgical Intervention
- Trans-Arterial Radioembolization for Hepatocellular Carcinoma: Sacco, R.; Giorgi, L.; Fornaro, L.; Bargellini, I.
- Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice: Cabibbo, G.; Petta, S.; Maida, M.; Cammà, C.

Surgical Intervention
Gastrointestinal Tumors

Editorial

165 Nutrition and Cancer
Fang, J.-Y. (Shanghai)

Mini-Reviews

166 Feeding Challenges in Patients with Esophageal and Gastroesophageal Cancers
Reim, D.; Friess, H. (Munich)

178 Nutrition in Patients with Gastric Cancer: An Update
Rosania, R.; Chiapponi, C.; Malfertheiner, P.; Venerito, M. (Magdeburg)

188 Nutrition and Hepatocellular Cancer
Schütte, K.; Schulz, C.; Malfertheiner, P. (Magdeburg)

195 Nutrition in Pancreatic Cancer: A Review

203 Nutrients Impact the Pathogenesis and Development of Colorectal Cancer
Du, W.; Fang, J.-Y. (Shanghai)

after 208 Contents Vol. 2, 2015